Dottorato in Medicina Molecolare

 

Sci. Rep. 2015 May 15; 5:10206

Real-time monitoring of cell protrusion dynamics by impedance responses.

Armando Gagliardi P, Puliafito A, di Blasio L, Chianale F, Somale D, Seano G, Bussolino F, Primo L.

Tuesday 21 March 2017

My Progress Report: "PDK1 targeting in mutated KRAS metastatic colorectal cancer"

held in Candiolo Cancer Institute

 

Friday 11 September 2015

My Progress Report: "Is PDK1 a therapeutic target for cancer?"

held at Candiolo Cancer Institute

 

ANNO 2017

Poster entitled: "PDK1 targeting in KRAS mutated metastatic colorectal cancer"

at MBC - September 19th 2017 - D-day 2017

 

ANNO 2016

Poster entitled: "PDK1 targeting in KRAS mutated metastatic colorectal cancer"

at EMBO EMBL Symposium "Organoids: Modelling organ development and disease in 3D culture"

held in Heidelberg, Germany - October 13th 2016

 

ANNO 2014

Poster entitled: "3-Phosphoinositide-Dependent Kinase 1 is required for anchorage independent growth of KRAS mutated cells"

at "Dangerous Liaisons: translating cancer biology into better patients management - 56° Congresso Nazionale Società Italiana di Cancerologia" 

held in Ferrara, September 12th 2014

 

ANNO 2017

EACR-AACR-SIC Special conference on the challenges of optimising immuno and targeted therapies from cancer biology to the clinic.

held in Florence, Italy - June 24th-27th 2017

(utilizzando il budget: quota 10% della borsa di dottorato)

 

ANNO 2016

EMBO EMBL Symposium "Organoids: Modelling organ development and disease in 3D culture"

held in Heidelberg, Germany - October 12th-15th 2016

(utilizzando il budget: quota 10% della borsa di dottorato)

 

ANNO 2015

1) "Frontiers in Regenerative Medicine"

held at the Molecular Biotechnology Center (MBC),  February 18th-20th 2015

2) The 2015 International Conference on Molecular Oncology "From Signal Transduction to Cancer Precision Medicine"

held at Candiolo Cancer Institute, June 6th-7th 2015

3) Beatson International Cancer Conference "Control of cell polarity and movement in cancer"

held at the Cancer Research UK Beatson Institute, Glasgow, Scotland. July 5th-8th 2105

(utilizzando il budget: quota 10% della borsa di dottorato)

 

ANNO 2014

1) Dangerous Liaisons: translating cancer biology into better patients management - 56° Congresso Nazionale Società Italiana di Cancerologia

held in Ferrara, September 11th-13th 2014

2) Conference "Molecular Clinical Oncology - Precision Medicine"

held at Candiolo Cancer Institute (TO), October 4th-5th 2014

 

ANNO 2017

held in Candiolo Cancer Institute:

1)   PDX-derived cell line models for pharmacogenomics studies in colorectal cancer
Tuesday 20 December 2016, Luca Lazzari

2)   Hijacking acquired resistance to anti-EGFR therapy  in colorectal cancer

Tuesday 24 January 2017, Sabrina Arena

3)   Next generation Liquid Biopsies: genotyping cancer in blood and other body fluids
Tuesday 21 February 2017, Giulia Siravegna

4)   Role of the postsynaptic adhesion molecule NLGN1 in cancer
Tuesday 28 February 2017, Margherita Pergolizzi

5)     Targeting the Met oncogene by concomitant inhibition of ligand and receptor by an antibody-decoy strategy
Tuesday 7 March 2017, Chiara Modica

6)     Targeting BRAF in colorectal cancer
Tuesday 28 March 2017, Daniele Oddo

7)     Loss of Neuroligin-2 promotes pancreatic ductal adenocarcinoma onset and progression by altering apical-basal polarity
Tuesday 2 May 2017, Emanuele Middonti

8)     Genomic evolution in colorectal cancer cells
Tuesday 16 May 2017, Nabil Amirouchene Angelozzi

9)     Precision medicine in colorectal cancer
Tuesday 23 May 2017, Silvia Marsoni

10)  Metabolic reprogramming as a driver of stemness and tumorigenesis in the intestine.
Tuesday 30 May 2017, Carlos Sebastian

11)  A pre-surgery protocol to investigate miR-100 as a predictor of response to hormonal therapy in breast cancer patients
Tuesday 6 June 2017, Annalisa Petrelli

12)  L1-MET alternative transcript in breast cancer
Tuesday 11 July 2017, Umberto Miglio

13)  Synergistic effect of BRAF and VEGF targeting in a BRAFV600E melanoma murine model
Tuesday 20 June 2017, Valentina Comunanza

14)  Metabolic vulnerability of KRAS-mutant colorectal cancer
Tuesday 5 September 2017, Alessia Mira

15)  Systematic screening for therapeutic targets in clinically aggressive colorectal cancer
Tuesday 12 September 2017, Federica Invrea

16)  Charting features and vulnerabilities of residual colorectal tumors surviving EGFR blockade
Tuesday 26 September 2017, Barbara Lupo

17)  TFEB inhibits fibroblast differentiation and activation program
Tuesday 3 October 2017, Elena Astanina

18)  Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
Tuesday 10 October 2017, Mariangela Russo

19)  A Sema3A mutant is an effective vascular normalizing and anti-cancer drug
Tuesday 24 October 2017, Federica Maione

20)  Role of  Neuroligin 1 and 2 in tumor-nervous-connections: approaches and issues
Tuesday 31 October 2017, Davide Pascal

21)  Cell population dynamics in a xenospheres colon cancer model
Tuesday 7 November 2017, Alberto Puliafito 

22)  Neuropilin-1 controls cancer cell adaptation to target therapies
Tuesday 14 November 2017, Sabrina Rizzolio

23)  Role of the transcription factor EB (TFEB) in angiogenesis and tumor progression
Tuesday 5 December 2017, Gabriella Doronzo

 

ANNO 2016

held at Candiolo Cancer Institute:

1) Regulation of Colorectal Cancer Stem Cells by Cytokine Networks: implications in self-renewal and resistance to therapies
Tuesday 24 November 2015, Viola Bigatto

2) Role of alpha6 integrin in pericytes dynamics and tumor vessels normalization
Tuesday 1 December 2015, Giulia Chiaverina

3) Semaphorin 6A and responsiveness to anti-EGFR targeted therapies in colorectal cancer
Tuesday 15 December 2015, Chiara Battistini

4) Semaphorin 6A and responsiveness to anti-EGFR targeted therapies in colorectal cancer
Tuesday 15 December 2015, Chiara Battistini

5) Strategies to improve half-life and potency of a Met therapeutic antibody
Tuesday 22 December 2015, Simona Cignetto

6) Collective directional migration in epithelial 3d models.
Tuesday 12 January 2016, Alberto Puliafito 

7) High-throughput screening to unravel the influence of protein phosphatases on VEGF-A signaling
Tuesday 19 January 2016, Maria Alvaro

8) Role of the endoplasmic reticulum in the control of neuropilin 1 traffic and endothelial cell adhesion
Tuesday 2 February 2016, Giulia Villari 

9) Intercepting acquired resistance to targeted therapies: how and when?
Tuesday 9 February 2016, Mariangela Russo

10) Caspase-mediated cleavage of MRCKα determines actin-myosin contraction and epithelial cell extrusion
Tuesday 1 March 2016, Paolo Gagliardi

11) Preclinical activity of Cytokine Induced Killer Cells (CIK) against sarcomas.
Tuesday 8 March 2016, Giulia Mesiano

12) RNA-based identification of actionable oncogenic drivers in colorectal cancer
Tuesday 15 March 2016, Sara Bellomo

13) Tfeb inhibits differentiation of coronary smooth muscle cells and fibroblasts by upregulation of TGF-β; and Notch pathways repressors

Tuesday 29 March 2016, Elena Astanina

14) TFEB governs a transcriptional program essential for angiogenic activities of VEGFR2
Tuesday 5 April 2016, Gabriella Doronzo

15) Xenospheres: a comprehensive patient-derived in vitro model to study response and resistance to targeted therapies in mCRC
Tuesday 26 April 2016, Paolo Luraghi

16) PPFIA1 drives active α5β1 integrin recycling from the TGN to control fibronectin fibrillogenesis and vascular morphogenesis

Tuesday 3 May 2016, Donatella Valdembri

17) Ras and Rab interacting protein 2 (RIN2) controls cell adhesion dynamics and signaling: implications for cancer angiogenesis and invasion
Tuesday 10 May 2016, Chiara Sandri

18) Generation of  a platform of gastro-esophageal PDXs to identify and validate molecular targets
Tuesday 17 May 2016, Prof. Silvia Giordano

19) AGNOSTOS Project: a platform to unveil the mysteries of cancer of unknown primary (CUPS)
Tuesday 24 May 2016, Silvia Benvenuti 

20) A potential strategy to counteract minimal residual disease in colorectal cancer after EGFR blockade.

Tuesday 31 May 2016, Barbara Lupo

21) Exploring glioblastoma heterogeneity at cancer stem cell level
Tuesday 7 June 2016, Francesca De Bacco

22) Precision oncology between challenges and opportunities: The example of colorectal cancer
Friday 10 June 2016, Prof. Livio Trusolino

23) The GEA platform as a tool to model gastric cancer therapy: focus on HER2
Tuesday 21 June 2016, Cristina Migliore

24) Cancer evolution as a therapeutic opportunity
Tuesday 28 June 2016, Prof. Alberto Bardelli 

25) Patient-derived tumor xenograft model to study intratumour heterogeneity of epithelial ovarian carcinomas
Friday 15 July 2016, Prof. Maria Flavia Di Renzo

26) Proteomic survey reveals novel neuropilin-1 partners and functions in vascular endothelial cells
Tuesday 13 September 2016, Noemi Gioelli

27) Targeting Semaphorin 4A-expressing myeloid cells to impair cervical cancer progression
Tuesday 20 September 2016, Yaqi Qiu

28) Targeting anti-apoptotic reprogramming to counteract drug tolerance in EGFR-inhibited colorectal tumors
Tuesday 27 September 2016, Simonetta Leto

29) Novel functions of PlexinD1 signaling: nuclear localization and transcriptional regulation
Tuesday 4 October 2016, Gabriella Cagnoni

30) RN-tre/USP6NL in breast cancer cell fitness
Tuesday 11 October 2016, Daniele Avanzato

31) Reviving 'oncogenic addiction' to MET bypassed by BRAF (G469A) mutation.
Thursday 3 November 2016, Anna Rita Virzi

32) Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth
Tuesday 8 November 2016, Giovanni Germano

33) Enabling permanent in vivo transduction of patient-derived xenografts
Tuesday 15 November 2016, Consalvo Petti

34) "Manipulating the Neuregulin1/ErbB system in peripheral nerves: an in vitro and in vivo laboratory investigation." Davide Pascal, Department of Clinical and Biological Sciences, Orbassano (Torino) - a post doctoral  applicant in Marco Arese laboratory (IRCCS)

 

ANNO 2015

held at Candiolo Cancer Institute:

1)    Effects of MET trafficking on cancer cells growth

Tuesday 27 January 2015, Emanuela Pupo

2)    Does chemotherapy affect the response to anti-EGFR therapy in colorectal cancer?

Tuesday 10 March 2015, Luca Lazzari

3)    Neuroligin 2: a synaptic protein modulates the release of the angiogenic factor Angiopoietin 2

Tuesday 17 March 2015, Elena Riccitelli 

4)    Somatic mutations and human diseases: the paradigm of PIK3CA mutations in cancer, CLOVES syndrome and vascular malformations

Tuesday 24 March 2015, Laura Di Blasio

5)    Characterizing the cross-talk between integrin mechanics and endocytosis

Tuesday 31 March 2015, Giulia Mana

6)    Neuroligins in nerve-tumor interactions

Tuesday 26 May 2015, Laura Bizzozero

7)    Genomics at the IRCC: the next generation

Tuesday 9 June 2015, The Bioinformatics Center (BIC)

8)     Resistance to MET inhibitors: which is the role of tumor microenvironment?

Tuesday 16 June 2015, Maria Apicella

9)     Tuesday 23 June 2015, Margherita Pergolizzi

10)    RN-tre in breast cancer

Tuesday 15 September 2015, Nadia Ducano

11)    Role of the synaptic protein Neuroligin-2 in the onset and progression of Pancreatic Ductal Adenocarcinoma

Tuesday 29 September 2015, Emanuele Middonti

12)    Evaluation of trabectedin and olaparib activity in preclinical models of bone and soft tissue sarcomas

Tuesday 20 October 2015, Ymera Pignochino

13)    Latrophilin 2/ADGRL2 controls class 3 semaphorin-to-Rap1 signaling and vascular morphogenesis

Tuesday 10 November 2015, Chiara Camillo

14) VEGF removal enhances the antitumor effect of BRAF inhibition by reprogramming the circuits between cancer and stroma

Tuesday 17 November 2015, Valentina Comunanza

 

PhD thesis:

held at Candiolo Cancer Institute:

1)    Monday January 26th 2015, Dr. Valentina Martin: "Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependance"

2)    Monday January 26th 2015, Dr. Erica Torchiaro: "RSK1 and RSK2 regulate motility and invasiveness of ovarian cancer cells"

held at the Molecular Biotechnology Center (MBC):

1)    Friday Febraury 06th 2015, Dr. Chiara Camillo

2)    Friday Febraury 06th 2015, Dr. Nadia Ducano

3)    Friday Febraury 06th 2015, Dr. Gioelli Noemi

 

ANNO 2014

held at Candiolo Cancer Institute:

1)     Tracking the Evolution of Drug Resistance by Genomic Barcoding.

Tuesday 11 November 2014, Beth Van Emburgh

2)     Stromal contribution to the colorectal cancer transcriptome

Tuesday 4 November 2014, Claudio Isella

3)     Killing circulating metastasis-initiating cells by MET-targeted Antibody-Dependent Cell-mediated Cytotoxicity
Tuesday 28 October 2014, Virginia Morello

4)     A translational approach for mCRC: updates on the "xenopatient-xenosphere-spheropatient" platform and results on RASwt xenospheres.
Tuesday 14 October 2014, Paolo Luraghi

5)     Real-time study of cell protrusion dynamics in response to growth factors: implications for cell migration and invasion
Tuesday 7 October 2014, Paolo Gagliardi

6)     A pre-surgery protocol to define miR-100 as a predictor of response
to hormonal therapy in breast cancer
Tuesday 16 September 2014, Annalisa Petrelli

7)     Notch signaling regulates PlexinD1 expression
Tuesday 9 September 2014, Michael Rehman

8)     Preclinical identification and validation of the NEDD8 pathway inhibitor Pevonedistat as an effective treatment for colorectal cancer
Tuesday 8 July 2014, Gabriele Picco

9)     Tfeb inhibits premature differentiation and migration of smooth muscle
cells progenitors during coronary vessel development.
Tuesday 1 July 2014, Elena Astanina

10)  Analysis of hepatocellular carcinoma progression
Tuesday 27 May 2014, Silvia Menegon

11)  Outlier kinase expression identifies new therapeutic targets for colorectal cancer
Tuesday 13 May 2014, Mariangela Russo

12)  Semaphorin and responsiveness to anti-EGFR targeted therapies in CRC
Tuesday 6 May 2014, Chiara Battistini

13)  Molecular characterization of RIN2, a key player of the Sema3/Plexin/R-Ras pathway in endothelial cells
Wednesday 23 April 2014, Chiara Sandri

14)  The transcription factor EB (TFEB): role in angiogenesis
Tuesday 15 April 2014, Gabriella Doronzo

15)  The dynamical response of EGFR from receptor activation to cell protrusions.
(Insights from modeling and experiments)
Tuesday 8 April 2014, Alberto Puliafito

16)  High-throughput screening to unravel the influence of protein phosphatases on vegf-a signaling
Tuesday 25 March 2014, Maria Alvaro

17)  RAF suppression improves the efficacy of MEK inhibitors in KRAS mutant colorectal cancer cells
Tuesday 18 March 2014, Simona Lamba

18)  TNF-alpha promotes invasive growth through the MET signaling pathway
Tuesday 11 March 2014, Viola Bigatto

19)  Characterizing the molecular mechanisms by which endothelial cells respond to class 3 semaphorins.

Monday 3 March 2014, Chiara Camillo

20)  The role of alpha6 Integrin in sprouting angiogenesis
Tuesday 25 February 2014, Giulia Chiaverina

21)  Development of 3D organoid culture to study the tumor-microenviroment interaction
Tuesday 18 February 2014, Valentina Comunanza

22)  HGF confers resistance to anti-angiogenic drugs by protecting colorectal cancer cells against metabolic stress
Tuesday 11 February 2014, Alessia Mira

23)  Zoledronic Acid improves anti-angiogenic therapy and chemotherapy by targeting M2-polarized Tumor-Associated Macrophages in a transgenic mouse model of cervical cancer
Tuesday 4 February 2014, Stefania Capano

24)  Mechanisms of acquired resistance to anti-EGFR targeted therapies in metastatic colorectal cancer
Tuesday 21 January 2014, Sandra Misale

25) The GTPase-Activating Protein RN-tre Controls Focal Adhesion Turnover and Cell Migration
Tuesday 14 January 2014, Nadia Ducano

26)  Tracking the Evolution of Drug Resistance by Genomic Barcoding.

Tuesday 11 November 2014, Beth Van Emburgh

27)  Regulation of sprouting angiogenesis by transcriptional and post-transcriptional network motifs
Tuesday 18 November 2014, Stefania Rosano

28)  Activation of RAS family members confers resistance to ROS1 targeting drugs
Tuesday 25 November 2014, Marilisa Cargnelutti

ANNO 2017

1)   "Clinical Translation of the Cancer Genome" by Prof. Elaine Mardis, Washington University School of Medicine, St. Louis (U.S.A.) - at IRCC - 14 December 2016

2)   AIRC Special Program "Molecular Clinical Oncology" Advisory Board Audit

at IRCC - 12/13 January 2017

3)   "Intratumor heterogeneity in brain cancer" by Prof. Joan Seoane, Ph.D. - ICREA Research, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
at IRCC - 19 January 2017

4)   "Liquid biopsy: Potential and challenges of circulating tumor cell research" by Prof. Klaus Pantel, M.D. - University Medical Center, Institute of Tumor Biology, Hamburg (Germany)
at IRCC - 19 January 2017

5)   "Understanding the role of BRCA2 tumour suppressor protein in DNA metabolism" by Prof. Vincenzo Costanzo

at IRCC - 28 February 2017

6)   "An integrated ATR, ATM and mTOR-mechanical network controlling nuclear plasticity and cell migration" by Prof. Marco Foiani

at IRCC - 3 March 2017

7)   Giornata Studio Guido Tarone

at MBC - 22 May 2017

8)   "Animal models as useful tools for the study of hepatocarcinogenesis?" by Prof. Amedeo Columbano, University of Cagliari, Italy

at MBC - 19 September 2017

9)    "Advanced genetic engineering to broaden gene therapy application to the treatment of inherited diseases and cancer?" by Prof. Luigi Naldini, "Vita-Salute" San Raffaele University, Milano, Italy

at MBC - 19 September 2017

10)  "Pro-invasive tumour-stroma interactions: role of cancer associated fibroblasts" by Sara Zanivan - Tumour Microenvironment and Proteomics Lab, CRUK Beatson Institute, Glasgow University

at IRCC - 10 November 2017

 

ANNO 2016

1) "Regulation of self renewal in Cancer Stem Cells"  by Prof. Pier Giuseppe Pelicci

held in the IRCCS, Friday 11 December 2015

2) "The impact of human retrotransposons on cancer" by Dr. Szilvia Solyom held in the IRCCS,  26 January 2016

3) "The transparent editorial process, data reproducibility and research integrity at EMBO"
by Roberto Buccione held in the IRCCS, Tuesday 22 March 2016

4) "Breast Cancer stem Cells targeting: a new step for intratumoral heterogeneity in the light of personalized medicine" by Prof. Emmanuelle Charafe Jauffret, Aix-Marseille Université, CRCM, Institut Paoli-Calmettes, CNRS, Marseille - held in the IRCCS, Friday 25 March 2016

5) "AIRC Support to Cancer Research: Strategies and Perspectives" by Prof. Federico Caligaris-Cappio, Scientific Director, Italian Association for Cancer Research, Milano - held in the IRCCS, Friday 29 April 2016

6) "Control of cell identity by polycomb group proteins " by Prof. Davide Pasini, Director of the Epigenetic mechanisms in stem cell differentiation and oncogenesis Unit, IEO Milano - held in IRCCS, Friday 27 May 2016

7) "Visualizing spatio-temporal signaling networks regulating cell fate and morphogenesis" by Prof. Olivier Pertz, Cellular Dynamics Lab, Institute of Cell Biology, University of Bern (Switzerland) - held in the IRCCS, Friday 17 June 2016

8) D-Day, held at the MBC, 15 September 2016

9) "Neutral evolution in cancer: distinguishing functional from nonfunctional intra-tumour heterogeneity" by Dr Andrea Sottoriva of the The Institute of Cancer Research, London, UK - on Monday, September 19th

10) "Mechanisms regulating tumor heterogeneity" by Prof. Cedric Blanpain, IRIBHM, Université Libre de Bruxelles (ULB). Held in IRCCS. Friday 21 October 2016

 

ANNO 2015

1)   Dr Normanno "Tumor heterogeneity in colon cancer: therapeutic implications"

held at Candiolo Cancer Institute, Monday January 26th

2)   "Il trasferimento di conoscenze in Ateneo: dalla ricerca alla valorizzazione dell'innovazione"

at the Campus Luigi Einaudi, February 3th 2015. Seminar organized by "Scuole di Dottorato" in collaboration with "Sezione Brevetti e trasferimento di Conoscenze"

3)   "Neuropilin and Integrin Control of Cancer Stem Cell Fate"

by Arthur Mercurio, University of Massachussetts Medical School, USA

held at Candiolo Cancer Institute, Friday 20 March 2015

4)   D-day 2015 della Scuola di Dottorato in Scienze della Vita e della Salute

held in "Aula Magna" at Rettorato dell'Università di Torino, September 16th 2015

 

A